UCL 1684 dibromide 

UCL 1684 (dibromide) is a first nanomolar, non-peptidic small conductance calcium-activated potassium (SK) channel blocker. UCL 1684 (dibromide) is effective in preventing the development of atrial fibrillation due to potent atrial-selective inhibition of I_Na. UCL 1684 (dibromide) causes atrial-selective prolongation of ERP secondary to induction of postrepolarization refractoriness^[1][2][3].

Potassium Channel^[1]

UCL 1684 (dibromide) (0.5 μM; HEK cells) produces direct atrial-selective inhibition of sodium channel current (I_Na) and shifts SS inactivation of the cardiac sodium channels. UCL 1684 (dibromide) (0.5 μM) induces PRR, decreases V _max, increases DTE, and extends the shortest S1-S1 interval^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

UCL 1684 (dibromide) (3 mg/kg; i.v.) increases wenckebach cycle length to 115.0±5.1 % of baseline value^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

654.44

C₃₄H₃₀Br₂N₄

199934-16-2

Solid

White to off-white

C12=[N+](CC3=CC(C[N+]4=CC=C(NCC5=CC=C(C=C5)CN6)C7=CC=CC=C47)=CC=C3)C=CC6=C1C=CC=C2.[Br-].[Br-]

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Burashnikov A, et al. The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity. J Cardiovasc Pharmacol. 2020;76(2)  [Content Brief]

  [2]. Rosa JC, et al. Bis-quinolinium cyclophanes: 6,10-diaza-3(1,3),8(1,4)-dibenzena-1,5(1,4)- diquinolinacyclodecaphane (UCL 1684), the first nanomolar, non-peptidic blocker of the apamin-sensitive Ca(2+)-activated K+ channel. J Med Chem. 1998;41(1):2-5.  [Content Brief]

  [3]. Diness JG, et al. Effects on atrial fibrillation in aged hypertensive rats by Ca(2+)-activated K(+) channel inhibition. Hypertension. 2011;57(6):1129-1135.  [Content Brief]